The FDA put a Class I recall on Beckman Coulter Inc.’s (NYSE:BEC) Synchron clinical chemistry analyzer.
The device is a computer-controlled clinical analyzer for determining chemistries in various fluids including blood, urine and cerebrospinal fluid.
The recall was initiated because the Synchron may exhibit ratio pump wear, silver iodide build-up on its chloride electrodes, microbial contamination, and maintenance that results in incorrect electrolyte results, according to the federal watchdog agency.
Beckman received a Product Corrective Action letter on April 5, 2011, according to the filing.
The recall is bad news for Danaher Corp. (NYSE:DHR), which agreed to acquire the company in a deal valued at about $6.8 billion earlier this year.
